nanodiag BW is one of seven selected clusters funded by the BMBF (during the second selection process) with the aim of converting nanopore technology into innovative products and services of personalized medicine. By this, diseases such as cancer, diabetes, cardiovascular, mental, neurodegenerative can be detected much earlier and treated in a much more targeted manner. The consortium of the cluster, coordinated by Hahn-Schickard, consists of well-known players such as the Freiburg University Hospital, the University of Freiburg, the Max Planck Institute for Immunobiology and Epigenetics, Freiburg and start-ups such as Ionera and Actome as well as other partners from Baden-Württemberg research organisations. They all focus on the research of nanopores as well as applying nanopore technology for future molecular diagnostics. NanodiagBW enables groundbreaking innovation by interlacing application-oriented research such as epigenetics or microbiology with basic research in physics, biochemistry and physiology as well as the emerging possibilities of bioinformatics, molecular dynamic simulations, artificial intelligence (AI) and machine learning. Meanwhile, micro- and nanofluidics together with microelectronics help to build integrated systems for the user.
